FI103202B1 - Menetelmä terapeuttisesti käyttökelpoisten 4-sulfonamido-1,4-dihydrokinoliiinijohdannaisten valmistamiseksi - Google Patents
Menetelmä terapeuttisesti käyttökelpoisten 4-sulfonamido-1,4-dihydrokinoliiinijohdannaisten valmistamiseksiInfo
- Publication number
- FI103202B1 FI103202B1 FI933762A FI933762A FI103202B1 FI 103202 B1 FI103202 B1 FI 103202B1 FI 933762 A FI933762 A FI 933762A FI 933762 A FI933762 A FI 933762A FI 103202 B1 FI103202 B1 FI 103202B1
- Authority
- FI
- Finland
- Prior art keywords
- sulfonamido
- preparation
- therapeutically useful
- dihydroquinoline derivatives
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66178091A | 1991-02-27 | 1991-02-27 | |
| US66178091 | 1991-02-27 | ||
| US70000491A | 1991-05-14 | 1991-05-14 | |
| US70000491 | 1991-05-14 | ||
| PCT/US1992/001093 WO1992015565A1 (en) | 1991-02-27 | 1992-02-11 | Nmda antagonists |
| US9201093 | 1992-02-11 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI933762A FI933762A (fi) | 1993-08-26 |
| FI933762A0 FI933762A0 (fi) | 1993-08-26 |
| FI103202B1 true FI103202B1 (fi) | 1999-05-14 |
| FI103202B FI103202B (fi) | 1999-05-14 |
Family
ID=27098383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI933762A FI103202B (fi) | 1991-02-27 | 1993-08-26 | Menetelmä terapeuttisesti käyttökelpoisten 4-sulfonamido-1,4-dihydroki noliiinijohdannaisten valmistamiseksi |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0573562B1 (fi) |
| JP (1) | JP3465794B2 (fi) |
| KR (1) | KR100224045B1 (fi) |
| AT (1) | ATE137225T1 (fi) |
| AU (1) | AU660969B2 (fi) |
| CA (1) | CA2104297C (fi) |
| DE (1) | DE69210229T2 (fi) |
| DK (1) | DK0573562T3 (fi) |
| ES (1) | ES2089511T3 (fi) |
| FI (1) | FI103202B (fi) |
| GR (1) | GR3019772T3 (fi) |
| HU (1) | HU217425B (fi) |
| NO (1) | NO180485C (fi) |
| WO (1) | WO1992015565A1 (fi) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5318985A (en) * | 1991-12-20 | 1994-06-07 | Merrell Dow Pharmaceuticals Inc. | Potentiation of NMDA antagonists |
| WO1994000124A1 (en) * | 1992-06-22 | 1994-01-06 | Eckard Weber | Glycine receptor antagonists and the use thereof |
| US5475007A (en) * | 1993-05-28 | 1995-12-12 | The Regents Of The University Of California | 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof |
| ATE176225T1 (de) * | 1993-11-29 | 1999-02-15 | Merrell Pharma Inc | Heterocyclische benzolsulfonyliminderivate als inhibitoren der il-1 wirkung |
| US5684017A (en) * | 1993-11-29 | 1997-11-04 | Merrell Pharmaceuticals Inc. | Benzenesulfonylimine derivatives as inhibitors of IL-1 action |
| IN2012DN06631A (fi) | 2010-02-16 | 2015-10-23 | Pfizer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8719102D0 (en) * | 1987-08-12 | 1987-09-16 | Merck Sharp & Dohme | Therapeutic agents |
| EP0386839B1 (en) * | 1989-03-08 | 1997-01-15 | Merck Sharp & Dohme Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
| NZ233641A (en) * | 1989-05-16 | 1992-07-28 | Merrell Dow Pharma | Quinoline and thienopyridine derivatives and excitatory amino acid antagonistic pharmaceutical compositions |
-
1992
- 1992-02-11 EP EP92907466A patent/EP0573562B1/en not_active Expired - Lifetime
- 1992-02-11 WO PCT/US1992/001093 patent/WO1992015565A1/en active IP Right Grant
- 1992-02-11 DE DE69210229T patent/DE69210229T2/de not_active Expired - Lifetime
- 1992-02-11 KR KR1019930702559A patent/KR100224045B1/ko not_active IP Right Cessation
- 1992-02-11 ES ES92907466T patent/ES2089511T3/es not_active Expired - Lifetime
- 1992-02-11 AU AU15320/92A patent/AU660969B2/en not_active Ceased
- 1992-02-11 JP JP50728592A patent/JP3465794B2/ja not_active Expired - Lifetime
- 1992-02-11 HU HU9302433A patent/HU217425B/hu not_active IP Right Cessation
- 1992-02-11 CA CA002104297A patent/CA2104297C/en not_active Expired - Lifetime
- 1992-02-11 AT AT92907466T patent/ATE137225T1/de not_active IP Right Cessation
- 1992-02-11 DK DK92907466.4T patent/DK0573562T3/da active
-
1993
- 1993-08-26 NO NO933042A patent/NO180485C/no not_active IP Right Cessation
- 1993-08-26 FI FI933762A patent/FI103202B/fi active
-
1996
- 1996-04-25 GR GR960401099T patent/GR3019772T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE137225T1 (de) | 1996-05-15 |
| HUT67301A (en) | 1995-03-28 |
| HU217425B (hu) | 2000-01-28 |
| EP0573562B1 (en) | 1996-04-24 |
| EP0573562A1 (en) | 1993-12-15 |
| CA2104297A1 (en) | 1992-08-28 |
| NO933042L (no) | 1993-08-26 |
| KR100224045B1 (ko) | 1999-10-15 |
| WO1992015565A1 (en) | 1992-09-17 |
| NO180485B (no) | 1997-01-20 |
| JP3465794B2 (ja) | 2003-11-10 |
| JPH06505746A (ja) | 1994-06-30 |
| CA2104297C (en) | 2003-05-27 |
| AU660969B2 (en) | 1995-07-13 |
| ES2089511T3 (es) | 1996-10-01 |
| FI933762A (fi) | 1993-08-26 |
| AU1532092A (en) | 1992-10-06 |
| DE69210229T2 (de) | 1996-11-14 |
| DK0573562T3 (da) | 1996-05-13 |
| KR930703257A (ko) | 1993-11-29 |
| FI933762A0 (fi) | 1993-08-26 |
| HU9302433D0 (en) | 1993-11-29 |
| FI103202B (fi) | 1999-05-14 |
| NO180485C (no) | 1997-04-30 |
| DE69210229D1 (de) | 1996-05-30 |
| GR3019772T3 (en) | 1996-07-31 |
| NO933042D0 (no) | 1993-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI890282A0 (fi) | Menetelmä terapeuttisesti käyttökelpoisten 23,24-didehydro-25-hydroksikalsiferolijohdannaisten valmistamiseksi | |
| FI102676B (fi) | Menetelmä terapeuttisesti käyttökelpoisten 3-amido- ja 3-sulfamidoindo lyylijohdannaisten valmistamiseksi | |
| FI98455B (fi) | Menetelmä terapeuttisesti aktiivisten indolijohdannaisten valmistamiseksi | |
| FI98454B (fi) | Menetelmä terapeuttisesti aktiivisten 3-indolyylitioasetaattijohdannaisten valmistamiseksi | |
| FI103202B1 (fi) | Menetelmä terapeuttisesti käyttökelpoisten 4-sulfonamido-1,4-dihydrokinoliiinijohdannaisten valmistamiseksi | |
| DE69230224D1 (de) | Potenzierung von nmda-antagonisten | |
| EE03027B1 (et) | Meetod 8-klorokinolooni derivaatide valmistamiseks | |
| FI97388B (fi) | Menetelmä heterosyklisten NMDA-antagonistien valmistamiseksi | |
| NO178375C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive NMDA-antagonister | |
| FI954169A0 (fi) | Menetelmä 3-substituoitujen 2-oksoindolijohdannaisten valmistamiseksi |